FDA orders more trials on PPD diabetes drug - Triangle Business Journal:

aqokeduiso.blogspot.com
Wilmington-based PPD (Nasdaq: is partnering with Takeda on the drug which is being developed for the treatment of type 2 Approval was expectedin 2009, a milestonwe that would have triggered a $25 million payment from Takeda to PPD. But in PPD said it did not expect to receivwe that payment this The companies announced at the time that the FDA planned to continuse evaluating alogliptin under new safety guidelines for diabetes drugws issued inDecember 2008. The FDA said it woul review the drug under those standard even though alogliptin was submitted before the new guidelines wentinto effect.
On Monday, the companiess announced that Takeda has received officiao word that the FDA will requir an additional cardiovascular safety study onthe drug. PPD employxs nearly 2,000 people in the Raleigh-Durham area.